Mike Ulz is Baird’s senior analyst covering Biotechnology. Prior to joining Baird in 2016, he was a vice president in equity research at Barclays and at J.P. Morgan. Prior to that, he was a research analyst at Piper Jaffray and at Thomas Weisel Partners. Mike has spent his entire equity research career covering the biotechnology sector. He also worked at the Columbia Genome Center conducting basic research in genomics. Mike received an MBA from Columbia Business School, an MA in Molecular Biology from Columbia Graduate School of Arts and Sciences, and a BS in Biology from Lafayette College.